ATARA BIOTHERAPEUTICS, INC. Restructuring Charges
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Restructuring Charges of $767.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for the quarter ending 2026-06-30 was $767.00K, a 49.64% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for the quarter ending 2025-12-31 was $1.25M.
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for the quarter ending 2025-09-30 was $27.00K.
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for fiscal 2025 was $12.61M, a 146.88% increase from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for fiscal 2024 was $5.11M, a 24.12% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for fiscal 2023 was $6.73M, a 12.84% increase from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. restructuring charges for fiscal 2022 was $5.96M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $767.00K 10-Q · filed 2026-08-12 | $767.00K 10-Q · filed 2026-08-12 | $2.01M derived: sum of 3 quarters · filed 2026-08-12 | $2.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $1.25M derived: sum of 2 quarters · filed 2026-05-12 | $1.27M derived: sum of 3 quarters · filed 2026-05-12 | $2.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.27M derived: sum of 2 quarters · filed 2026-03-16 | $2.79M derived: sum of 3 quarters · filed 2026-08-12 | $12.61M 10-K · filed 2026-03-16 |
| 2025-09-30 | $27.00K 10-Q · filed 2025-11-12 | $1.55M derived: sum of 2 quarters · filed 2026-08-12 | $11.36M 10-Q · filed 2025-11-12 | $11.36M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.52M 10-Q · filed 2026-08-12 | $11.34M 10-Q · filed 2026-08-12 | $11.34M derived: sum of 3 quarters · filed 2026-08-12 | $11.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $9.81M 10-Q · filed 2026-05-12 | $9.81M derived: sum of 2 quarters · filed 2026-05-12 | $9.81M derived: sum of 3 quarters · filed 2026-05-12 | $10.17M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $356.00K derived: sum of 3 quarters · filed 2026-03-16 | $5.11M 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $356.00K derived: sum of 2 quarters · filed 2025-11-12 | $5.11M 10-Q · filed 2025-11-12 | $11.79M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $356.00K 10-Q · filed 2025-08-11 | $5.11M 10-Q · filed 2025-08-11 | $11.79M derived: sum of 3 quarters · filed 2025-08-11 | $11.79M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $4.75M 10-Q · filed 2025-05-15 | $11.44M derived: sum of 2 quarters · filed 2025-05-15 | $11.44M derived: sum of 3 quarters · filed 2025-05-15 | $11.44M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $6.68M derived: sum of 2 quarters · filed 2025-03-07 | $6.68M derived: sum of 3 quarters · filed 2025-03-07 | $6.73M 10-K · filed 2025-03-07 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $45.00K 10-Q · filed 2024-11-12 | $119.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | $45.00K 10-Q · filed 2024-08-12 | $119.00K derived: sum of 3 quarters · filed 2024-08-12 | $6.01M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $45.00K 10-Q · filed 2024-05-09 | $119.00K derived: sum of 2 quarters · filed 2024-05-09 | $6.01M derived: sum of 3 quarters · filed 2024-05-09 | $6.01M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $5.96M derived: sum of 2 quarters · filed 2024-03-28 | $5.96M derived: sum of 3 quarters · filed 2024-03-28 | $5.96M 10-K · filed 2024-03-28 |
| 2022-09-30 | $5.89M 10-Q · filed 2023-11-01 | $5.89M derived: sum of 2 quarters · filed 2023-11-01 | $5.89M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |